All articles by cmsadmin 

  1. Pfizer yet to make divestment decisions

    Pfizer has yet to make a definitive decision over its non-core businesses, contradicting previous reports that indicated its nutritionals division…
    Read More…

    15 Sep
  2. Technology Strategy Board to support healthcare research projects

    The Technology Strategy Board, in collaboration with the Engineering and Physical Sciences Research Council, is set to invest up to…
    Read More…

    15 Sep
  3. BioSante completes LibiGel pharmacokinetic study

    Speciality pharmaceutical company BioSante Pharmaceuticals has completed the pharmacokinetic study of LibiGel, a transdermal testosterone gel for the treatment of…
    Read More…

    14 Sep
  4. Silence Therapeutics partners with InteRNA to develop cancer therapeutics

    Silence Therapeutics and InteRNA Technologies have agreed to combine the delivery capabilities of Silence’s proprietary AtuPLEX delivery system with InteRNA’s…
    Read More…

    14 Sep
  5. Spencer Pharmaceutical rejects Hail First acquisition offer

    Hail First Pharma’s $250m offer to acquire the newly formed US firm Spencer Pharmaceutical has been rejected. Spencer Pharmaceutical said…
    Read More…

    14 Sep
  6. GlaxoSmithKline teams up with McLaren

    GlaxoSmithKline has formed a partnership with Formula 1 team McLaren in the hope of driving its manufacturing operations and research…
    Read More…

    14 Sep
  7. API compliance – safeguarding the supply chain

    The problem of falsified medicines is substantial and growing. According to European Customs’ statistics, between 2006 to 2009 the number…
    Read More…

    14 Sep
  8. Teva increases stake in CureTech

    Israel-based pharmaceutical major Teva has increased its stake in CureTech to 75% with an investment of $19m, due to positive…
    Read More…

    13 Sep
  9. Merck rubbishes Bachmann HPV claims

    Merck has rejected claims by Republican US presidential candidate Michele Bachmann that human papilloma virus (HPV) vaccine Gardasil could cause…
    Read More…

    13 Sep
  10. NKTR-102 shows efficacy against breast cancer

    Nektar Therapeutics has presented positive Phase II study results of NKTR-102 in patients with metastatic breast cancer. NKTR-102, a topoisomerase…
    Read More…

    13 Sep
Close
Close
Close

Go Top